Editorial · 19 Jun 2026
Conference abstractPublished 26 Nov 2018
Bi- or multifunctional opioid analgesics
Montreal Clinical Research Institute, CanadaUniversity of Montreal, Canada
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Acute pain typically responds well to treatment with opioids and NSAIDs, whereas neuropathic pain is difficult to treat with only 40-60% of patients achieving pain relief. Currently used treatments, including tricyclic antidepressants, serotoninnorepinephrine reuptake inhibitors, anticonvulsants and morphine are either ineffective or produce major, limiting side effects. Our goal is to develop opioids with novel bi- or multifunctional activity profiles for treatment of chronic pain with minimal side effects. [Dmt1]DALDA (SS-02), a tetrapeptide with excellent drug-like properties, is a potent mu opioid analgesic and also is a mitochondria-targeted antioxidant. Mitochondrial reactive oxygen species (ROS) play a key role in mechanisms of neuropathic pain and there is evidence that ROS quenchers synergize with opiates in alleviating neuropathic pain. As expected, SS-02 turned out to be more effective than morphine in a rat model of neuropathic pain. Similarly, in a rat model of complex regional pain syndrome (CRPS-1), SS-02 and one of its analogues produced an up to 70-fold more potent and longer-lasting analgesic effect as compared to morphine. A structurally related peptide (SS-20) capable of promoting mitochondrial energetics had a protective effect against the development of chemotherapy-induced peripheral neuropathy in mice. Thus, these compounds are excellent drug candidates for neuropathic pain treatment. In a different approach we developed bifunctional compounds that target two distinct receptors. On the basis of a strong pharmacological rationale compounds were designed that act as agonists at the mu opioid receptor (MOR) and as antagonists at the delta opioid receptor (DOR). Such MOR agonist/DOR antagonists turned out to be potent analgesics in the rat tail flick test with low propensity to produce analgesic tolerance and dependence. Furthermore, bifunctional MOR agonist/NK1 receptor antagonists and opioid agonist/nociceptin antagonists were more potent than morphine in a neuropathic pain model and in one case did not produce respiratory depression. Recent Publications 1. Schiller P W, Nguyen TM-D, Saray A, Poon A W H, Laferrière A and Coderre T J (2015) The bifunctional μ opioid agonist/ antioxidant [Dmt1]DALDA is a superior analgesic in an animal model of complex regional pain syndrome-type 1. ACS Chemical Neuroscience 6:1789-1793. 2. Toyama S, Shimoyama N, Szeto H H, Schiller P W and Shimoyama M (2018) Protective effect of a mitochondria-targeted peptide against the development of chemotherapy-induced peripheral neuropathy in mice. ACS Chemical Neuroscience DOI: 10.1021/acschemneuro.8b00013. 3. Ballet S, Betti C, Novoa A, Tömböly C, Nielsen C U, Helms H C, Lesniak A, Kleczkowska P, Chung N N, Lipkowski A W, Brodin B, Tourwé D and Schiller W (2014) In vitro membrane permeation studies and in vivo antinociception of glycosylated Dmt1-DALDA analogues. ACS Medicinal Chemistry Letters 5:352-357. 4. Betti C, Mika J, Dyniewicz J, Frankiewicz L, Novoa A, Keresztes A, Kosson P, Van Duppen J, Chung N N, Vandenbroeck J, Lipkowski A W, Schiller P W, Przewlocka B, Tourwé D and Ballet S (2015) Dual alleviation of acute and neuropathic pain by fused opioid agonist-neurokinin 1 antagonist peptidomimetics. ACS Medicinal Chemistry Letters 6:1209-1214. 5. Guillemyn K, Starnowska J, Lagard C, Dyniewicz J, Chung NN, Kosson P, Lipkowski A W, Chevillard L, Megarbane B, Tourwé D, Simonin F, Przewlocka B, Schiller P W and Ballet S (2016) Bifunctional and peptide-based opioid agonistnociceptin antagonist ligands for dual treatment of acute and neuropathic pain. Journal of Medicinal Chemistry 59:3777- 3792.
Subjects
Anaesthesia & PainAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pain & Relief.
Editorial · 29 May 2026
Pain: A Biopsychosocial Journey Of Complexity
Editorial · 29 Dec 2025
Digital Health Revolutionizes Pain Management: A New Era
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pain & Relief
- SubjectAnaesthesia & Pain
- BylineArticles whose byline prints “Peter W. Schiller”
